Trial record 2 of 2 for:
cindome
A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04026997 |
|
Recruitment Status :
Recruiting
First Posted : July 19, 2019
Last Update Posted : November 5, 2020
|
Sponsor:
CinDome Pharma, Inc.
Information provided by (Responsible Party):
CinDome Pharma, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This is a randomized, double-blind, placebo-controlled Phase 2A study to evaluate safety, efficacy, PK, and dose response of oral CIN-102 in adults with idiopathic and diabetic gastroparesis. The study will assess three oral doses of CIN-102 versus placebo in three separate cohorts.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Gastroparesis | Drug: CIN-102 Dose 1 Drug: CIN-102 Dose 2 Drug: CIN-102 Dose 3 Drug: Placebo | Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 60 participants |
| Allocation: | Randomized |
| Intervention Model: | Sequential Assignment |
| Masking: | Triple (Participant, Care Provider, Investigator) |
| Primary Purpose: | Treatment |
| Official Title: | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Dose Response of Oral CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis |
| Actual Study Start Date : | September 11, 2019 |
| Estimated Primary Completion Date : | December 2020 |
| Estimated Study Completion Date : | March 2021 |
Resource links provided by the National Library of Medicine
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Cohort 1
CIN-102 tablets by mouth twice daily for 14 days
|
Drug: CIN-102 Dose 1
CIN-102 Dose 1 |
|
Placebo Comparator: Cohort 1 - Placebo
Placebo tablets by mouth twice daily for 14 days
|
Drug: Placebo
Placebo |
|
Experimental: Cohort 2
CIN-102 tablets by mouth twice daily for 14 days
|
Drug: CIN-102 Dose 2
CIN-102 Dose 2 |
|
Placebo Comparator: Cohort 2- Placebo
Placebo tablets by mouth twice daily for 14 days
|
Drug: Placebo
Placebo |
|
Experimental: Cohort 3
CIN-102 tablets by mouth twice daily for 14 days
|
Drug: CIN-102 Dose 3
CIN-102 Dose 3 |
|
Active Comparator: Cohort 3- Placebo
Placebo tablets by mouth twice daily for 14 days
|
Drug: Placebo
Placebo |
Primary Outcome Measures :
- Change from baseline in gastric emptying [ Time Frame: Baseline (gathered on Days -10 to -3) to Day 14 ]
Secondary Outcome Measures :
- Change from baseline in gastric emptying terminal phase elimination half life [ Time Frame: Baseline (gathered on Days -10 to -3) to Day 14 ]
- The change from baseline in ANMS GCSI-DD total scores [ Time Frame: Day -14 to 14 ]
- The change from baseline in ANMS GCSI-DD subscale scores [ Time Frame: Day -14 to 14 ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Male and female patients 18 to 70 years old.
- Current diagnosis of idiopathic or diabetic gastroparesis OR documented delayed gastric emptying.
- Presence of moderate to severe nausea.
- Body mass index (BMI) between 18 and 40 kg/m2, inclusive.
- Glycosylated hemoglobin level <11% at Screening.
- Willing to washout from ongoing treatment for gastroparesis.
- Able to understand and willing to comply with all study visits, procedures, restrictions, and provide written informed consent according to institutional and regulatory guidelines.
Exclusion Criteria:
- Other known disorder or treatment which could explain or contribute to symptoms of gastroparesis.
- Positive test for drugs of abuse at the screening or evaluation visits.
- Personal or family history of prolonged heart rate-corrected QT.
- History or evidence of clinically significant arrhythmia.
- History of gastrectomy, fundoplication, vagotomy, pyloroplasty, or bariatric surgery.
- Females who are pregnant, nursing, or planning on becoming pregnant during the study.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04026997
Contacts
| Contact: Brendan Doran, PharmD | +1-844-531-1834 | bdoran@cinrx.com |
Locations
Show 19 study locations
Sponsors and Collaborators
CinDome Pharma, Inc.
| Responsible Party: | CinDome Pharma, Inc. |
| ClinicalTrials.gov Identifier: | NCT04026997 |
| Other Study ID Numbers: |
CIN-102-121 |
| First Posted: | July 19, 2019 Key Record Dates |
| Last Update Posted: | November 5, 2020 |
| Last Verified: | November 2020 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Gastroparesis Stomach Diseases Gastrointestinal Diseases |
Digestive System Diseases Paralysis Neurologic Manifestations |